NCT04509102View on ClinicalTrials.gov

Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Major Depressive Disorder
Interventions
DRUG

Adderall-XR

Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.

DRUG

Placebo

Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.

Trial Locations (1)

90025

UCLA Semel, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER